Biography: Siyaram Pandey is a Distinguished University Professor of Biochemistry at the University of Windsor. He obtained his PhD from JNU (Delhi) and CCMB Hyderabad, India, did postdoctoral training at McGill University, worked at NRC, Ottawa before joining the University of Windsor. His research is focused on apoptosis and its role in neurodegenerative diseases and cancer. He has published more than 93 research articles and has 2 patents. He was President of the Natural Health Product Research Society of Canada (2013-1015). His discovery of the novel natural anti-cancer Dandelion Root extract has progressed to clinical trial for drug-refractory cancers in Canada. His research team has demonstrated that Ubisol Q10 (a water-soluble formulation of Coq10 and Ashwagandha extract in combination are capable of halting the progression of neurodegeneration, motor and cognition deficits in rodent models of AD and PD. He has been working in collaboration with Nextremedies Inc to develop this neuroprotective therapy. He has been working in collaboration with Synthite Industries ltd, India, Shogun Maitake Canada Company ltd. on the development of anticancer herbal extracts for the supplementary therapy of cancer patients. He is member of Society of Toxicology, USA, and Academic Editor for PLoS ONE, Associate editor for Evidence Based Complementary and Alternative Medicine (ECAM), IJMS, Integrative Cancer Therapies, Journal of Alzheimer’s disease.
Biography: Siyaram Pandey is a Distinguished University Professor of Biochemistry at the University of Windsor. He obtained his PhD from JNU (Delhi) and CCMB Hyderabad, India, did postdoctoral training at McGill University, worked at NRC, Ottawa before joining the University of Windsor. His research is focused on apoptosis and its role in neurodegenerative diseases and cancer. He has published more than 93 research articles and has 2 patents. He was President of the Natural Health Product Research Society of Canada (2013-1015). His discovery of the novel natural anti-cancer Dandelion Root extract has progressed to clinical trial for drug-refractory cancers in Canada. His research team has demonstrated that Ubisol Q10 (a water-soluble formulation of Coq10 and Ashwagandha extract in combination are capable of halting the progression of neurodegeneration, motor and cognition deficits in rodent models of AD and PD. He has been working in collaboration with Nextremedies Inc to develop this neuroprotective therapy. He has been working in collaboration with Synthite Industries ltd, India, Shogun Maitake Canada Company ltd. on the development of anticancer herbal extracts for the supplementary therapy of cancer patients. He is member of Society of Toxicology, USA, and Academic Editor for PLoS ONE, Associate editor for Evidence Based Complementary and Alternative Medicine (ECAM), IJMS, Integrative Cancer Therapies, Journal of Alzheimer’s disease.